Skip to main content
OpenTrials
Completed

NCT Number: NCT03790917

Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY

A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.

Primary Study Objective(s) Primary study objective The aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with CV disease complicated by non-valvular atrial fibrillation requiring OAC treatment within the outpatient registry PROFILE (prospective, observational study).

1. Data collection in patients with non-valvular atrial fibrillation requiring OAC treatment included in the registry 2. Evaluation of actual patient adherence to OACs

Secondary Study Objective(s)

1. Evaluation of potential patient adherence to OACs 2. Determination of the most significant factors associated with adherence to OACs in patients with non-valvular AF 3. Validation of new original 5-item Questionnaire 4. Evaluation of doctor's adherence to OAC prescription according to Guidelines (ESC). Management of atrial fibrillation,2016)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Research Center for Preventive Medicine

Moscow, 101990, Russia

About this study

AF patients from ongoing PROFILE registry will be invited to visit the scientific center.

2 visits with a 6-month interval are expected for each patient as part of routine clinical practice and phone contact is scheduled for each patient 1 year from the first visit to the scientific center (follow-up period).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women above 18 years of age who were included in the PROFILE registry by the start of the observational study
  • Presence of written informed consent to participate in the study, fill in the study questionnaires and have personal data analyzed
  • Presence of any form of non-valvular atrial fibrillation with CHA2DS2-VASc score of ≥1 or patients with CHA2DS2-VASc score = 0, who are already taking OAK

Exclusion criteria

  • Patients with high bleeding risk, including patients with:
  • Congenital or acquired bleeding disorders
  • Uncontrolled resistant hypertension
  • Exacerbation of gastric and duodenal ulcer
  • Vascular retinopathy
  • Recent history of intracranial or intracerebral hemorrhage
  • Pathology of the brain and spinal cord vessels
  • Recent history of brain, spinal cord or eye surgery
  • History of bronchiectasis or pulmonary hemorrhage
  • A CHA2DS2-VASc score of 0 (OACs are not indicated)
  • Pregnancy, lactation
  • Planned surgery
  • Known hypersensitivity to ingredients of medications used in the study

Treatment and study plan

Primary outcomes

  1. Proportions of Adherent, Partially Adherent, Partially Non-adherent and Completely Non-adherent Patients (NSEPh During V1)

    Time frame: 6 months

    The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs.

    Adherence to therapy was assessed during V1 with the use of the original questionnaire - National society of evidence-based pharmacotherapy (NSEPh) adherence scale.

  2. Proportions of Adherent, Partially Adherent, Partially Non-adherent and Completely Non-adherent Patients (NSEPh During Phone Contact)

    Time frame: 1 year

    The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs.

    Adherence to therapy was assessed during phone contact with the use of the original questionnaire - National society of evidence-based pharmacotherapy (NSEPh) adherence scale.

    Out of 201 participants of the study 4 patients died and 197 patients completed the study.

Secondary outcomes

  1. Proportion of Potentially Adherent Patients

    Time frame: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)

    Specifically designed 5-item questionnaire was used for assessment of potential adherence to OACs. According to results patients were divided into groups: completely adherent, partially adherent, completely non-adherent to OACs.

  2. Proportion of OACs Prescribed by Doctors According to Guidelines

    Time frame: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)

    Prescription of OACs according to guidelines was considered "positive" if it matched the key points of 2016 ESC Guidelines for the management of atrial fibrillation.

    • Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc score of 2 or more.
    • Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc score of 3 or more.
    • Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk.
    • NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or moderate-to-severe mitral stenosis (Level of evidence C).
    • In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not recommended for stroke prevention.

  3. The Main Reasons for Refusing to Start NOAC Therapy

    Time frame: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)

    The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs. Patients refusing to start NOAC treatmet were asked about the reasons to refuse NOAC treatment.

  4. Reasons for Stopping Oral Anticoagulants (Data From Visit 1)

    Time frame: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC))

    The study consisted of two visits half a year apart (V0, V1) and phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs. Patients who stopped or didn't start NOAC treatment were asked about the reasons for non-adherence to anticoagulants use during visit 1 (6 months) and at PC (1 year).

  5. Reasons for Stopping Oral Anticoagulants (Data From the Phone Contact)

    Time frame: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)

    The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs. Patients who stopped NOAC treatmet were asked about the reasons for stopping oral anticoagulants (NOAC and warfarin) use during the phone contact.

Sponsors and collaborators

Lead sponsor

National Research Center for Preventive Medicine

Other Gov

Registry information

Official study title

Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY Profile. Prospective Observational Study. ANTEY Study

Acronym: ANTEY

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jan 2, 2019
Registry last updated
Jul 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.